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Crohn’s disease (CD) is a chronic, relapsing inflammatory disorder that can occur
anywhere along the gastrointestinal tract. The precise etiology of CD is still unclear but it
is widely accepted that a complex series of interactions between susceptibility genes, the
immune system and environmental factors are implicated in the onset and perpetuation
of the disease. Increasing evidence from experimental and clinical studies implies the
intestinal microbiota in disease pathogenesis, thereby supporting the hypothesis that
chronic intestinal inflammation arises from an abnormal immune response against the
microorganisms of the intestinal flora in genetically susceptible individuals. Given that
CD patients display changes in their gut microbiota composition, collectively termed
“dysbiosis,” the question raises whether the altered microbiota composition is a cause of
disease or rather a consequence of the inflammatory state of the intestinal environment.
This review will focus on the crosstalk between the gut microbiota and the innate immune
system during intestinal inflammation, thereby unraveling the role of the microbiota in CD
pathogenesis.
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Introduction
Crohn’s disease (CD) is a chronic, relapsing inflammatory disorder affecting the gastrointestinal tract
and together with ulcerative colitis (UC) commonly included in the collective term inflammatory
bowel diseases (IBD). Inflammation associated with CD is characterized by a discontinuous,
transmural pattern, and can affect any part of the gastrointestinal tract (1). Although the precise
etiology of CD remains unclear, several factors are believed to play a role in its development and
progression. Given the results from genome-wide association studies (GWAS), it is undisputed
that genetic susceptibility plays an important role in disease development (2, 3). Among immune-
related conditions, CD is special in that the genetic contribution to disease is high with concordance
rates up to 50% among monozygotic twins (4, 5). However, in countries that have adopted a
“modernized” lifestyle the incidence rates of IBD have steeply increased in the last few decades.
These epidemiological observations clarify that the host genotype alone accounts for a significant but
limited proportion of CD risk and rather underline the multifactorial nature of the disease (6–10).
The role of the intestinalmicrobiota in disease pathogenesis has becomemore andmore appreciated.
Evidence from genetic, immunological, and microbial studies implicates that chronic intestinal
inflammation results from a dysregulated immune response toward components of the commensal
intestinal microbiota in genetically susceptible individuals (11). This perception is supported by
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the identification of several risk loci associated with CD, including
genes involved in intracellular processing and killing of bacteria
(e.g., NOD2, ATG16L1, IRGM) (12, 13).
Starting with the intestinal lumen, the first part of this review
will focus on the intestinal microbiota composition and its
changes during inflammation. In the following sections, we will
then take a closer look at deeper layers of the intestinal tissue to
dissect the interplay of the intestinal microbiota with cells of the
host immune system.
Human Intestinal Microbiota
Intestinal Microbiota – Composition
The assembly of the human gut microbiota starts during birth
with Bifidobacterium and Lactobacillus derived from the vaginal
canal and breast milk displaying the microorganisms that initially
colonize the human intestinal tract (14). During adolescence,
phylogenetic diversity of themicrobial community increases lead-
ing to a complex, diverse, and dynamic microbiota. The adult
human gastrointestinal tract contains an abundant microflora,
including bacteria, archaea, eukarya, and viruses (15). Recent
development of culture-independentmolecular profilingmethods
has greatly advanced our understanding of the microbiome (16).
Nowadays, the composition of microbial communities is typically
evaluated by targeting the bacterial 16S ribosomal RNA gene as a
phylogenetic marker (15). These culture-independent molecular
techniques indicate that the humanmicrobiota contains about 200
strains of bacteria comprising over 100 different bacterial species,
dominated by just a few phyla (16). Even though these techniques
revealed a high level of variability between individuals at the
bacterial species level, Firmicutes and Bacteroidetes represent the
predominant phyla across all vertebrates, representing over 90%
of all intestinal bacteria. It is assumed that the individual compo-
sition of the microbiota is relatively stable over time, a term called
“resilience.” Factors that promote microbial diversity in healthy
adults include diet, environment, gender, and genetics among
others (17, 18). Studies focusing on gutmicrobiota profiles of adult
humans with varying degrees of genetic relatedness effectively
demonstrated the impact of genetic and environmental factors on
gut microbiota development. The intestinal microbiota composi-
tion of monozygotic twins indicated a high degree of similarity,
but was yet distinct. Individuals who were living in the same envi-
ronment and shared similar eating habits showed the least similar-
ity, while siblings displayed an increased similarity in their species
profile (1, 19). Recent studies in nucleotide-binding oligomeriza-
tion domain 2 (Nod2)-deficient mice and humans carryingNOD2
variants point to an essential role of Nod2 for the development
and composition of the host microbiota. Nod2-deficient mice
displayed an increased load of commensal microbiota and an
altered microbiota composition. Additional studies in weaning
mice illustrated that NOD2 may affect the microbial community
early in life. Furthermore, the substantial changes in the micro-
biota composition caused by Nod2 deficiency was paralleled by
an increased colitis severity following chemically induced injury.
Subsequent co-housing and cross-feeding experiments revealed
the transmissibility of the observed genotype-dependent disease
risk (20). Taken together, these studies clearly indicated that the
host genotype has a lasting effect on the intestinal microbiota
composition and vice versa the intestinal microbiota is capable of
determining the host phenotype.
Intestinal Microbiota – Shaping the
Gastrointestinal Immune System
In health, the relationship between the host and the intesti-
nal microbiota provides mutual benefits. On the one hand, the
microbiota benefits from the nutrient-rich environment of the
gut paving the way for the establishment of a relatively stable
ecosystem. In turn, the intestinal microbiota enriches the host
with vital functions that the host itself cannot perform. The
intestinal microbiota is substantial for mucosal barrier function,
affects the development of the mucosal immune system, and is
essential for a number of physiological metabolic processes as
described further on (21). The profound effects of the commensal
microbiota on intestinal and immune cell development have best
been highlighted by the engraving phenotype of germ-free (GF)
mice. One of the first deficiencies observed in GF mice was a
profound reduction of secretory immunoglobulin A (IgA) levels
in the intestine. Subsequent mono-association of these mice with
various bacteria was shown to lead to an increased IgA expression
(22). In addition to numerous defects in antibody production,
GF mice display various morphological tissue defects in their
intestines [Table 1; (23)]. These developmental impairments are
attenuated following the introduction of gut bacteria, once more
illustrating the indispensable connection between the ultrastruc-
tural development of the intestine and the commensal microbiota.
Next to defects in intestinal organ development, investigations
on GF mice also revealed cellular defects in intestinal epithe-
lial and lamina propria lymphocytes as well as in mesenteric
lymph nodes (Table 1). Normal functioning of intestinal epithelial
cells, including the expression of microbial recognition receptors,
TABLE 1 | Defects in the intestinal mucosal immune system in GF mice.
Defects in intestinal organ development in germ-free (GF) mice
Site Phenotype in GF mice
Small
intestine
Peyer’s patches Fewer, less cellular
Lamina propria Thinner, less cellular
Germinal centers Fewer plasma cells
Isolated lymphoid follicles Smaller, less cellular
MLN Germinal centers Smaller, less cellular
Fewer plasma cells
Cellular defects in germ-free (GF) mice
Cell type Phenotype in GF mice
IEL CD8+ T cells Fewer, reduced cytotoxicity
LPL CD4+ T cells Proportional decrease in number
CD4+ T cells Decreased Th17 cells (small intestine)
CD4+ T cells Increased Th17 cells (colon)
MLN CD4+CD25+ T cells Reduced expression of FoxP3
CD4+CD25+ T cells Reduced suppressive capacity
IEL, intestinal epithelial lymphocytes; LPL, lamina propria lymphocytes; MLN, mesenteric
lymph nodes; GF, germ free [adapted from Ref. (23)].
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defensins, and antimicrobial peptides (AMPs), was shown to be
impaired in GF animals compared to their conventionally raised
counterparts (23).
Detailed investigations on certain members of the intestinal
microbiota served to unravel mechanisms by which commensal
bacteria induce immune tolerance. For example, investigations
on segmented filamentous bacteria (SFB) revealed that these
Gram-positive bacteria are sufficient to promote T helper 17 cells
(Th17) development in the small intestinal lamina propria (24).
In addition, colonization of GF mice with SFB resulted in an
increased production of serum amyloid A in the terminal ileum,
which in turn enhanced IL-6 and IL-23 production by lamina
propria dendritic cells (DCs), thereby stimulating a Th17 inducing
environment (24). Th17 effector cytokines enhance epithelial cell
tight junctions, induce mucin production, and have been associ-
ated with induction of AMPs. Colonization of GF mice with SFB
resulted in the induction of multiple AMP genes, for example,
RegIIIγ (24). Even though Th17 cells are crucial for protecting
the host against pathogenic infection, it should be noted that
these cells also display an inflammatory potential as observed
in different murine models of autoimmune diseases (25, 26).
Recently, certain strains within Clostridia clusters XIVa, IV, and
XVIII were shown to induce regulatory T cell (Treg) responses
in the colon (27). Another prominent human commensal, Bac-
teroides fragilis, was found to direct the development of FoxP3+
Tregs via the immunomodulatory molecule polysaccharide A.
Monocolonization of GF mice with B. fragilis was accompanied
by an increased suppressive Treg capacity and the induction of an
anti-inflammatory cytokine profile emerging fromFoxP3+ T cells
in the gut (28).
Intestinal Microbiota – Metabolic Functions
Next to their ability to promote immune system development
and maturation as outlined above, the intestinal microbiota
enriches the host with metabolic functions by synthesizing vita-
mins and degrading complex indigestible dietary carbohydrates
and proteins. Fermentation of dietary fiber leads to the pro-
duction of short chain fatty acids (SCFAs), primarily acetate,
propionate, and butyrate (21, 29). The functions of SCFAs in
promoting colonic health range from displaying a unique energy
source for colonocytes to mediating anti-inflammatory and anti-
tumorigenic effects (30). Therefore, it is easily comprehensible
that conditions coming along with reduced SCFA-levels, includ-
ing diversion colitis, fiber-free diet, or GF conditions, present
with metabolic starvation and consecutive colonic atrophy (31).
Among SCFAs, butyrate has received most attention for its effects
on colonic health. Butyrate displays an anti-inflammatory effect
by decreasing the expression of pro-inflammatory cytokines via
inhibition of NF-κB activation and was shown to exert the abil-
ity to influence gene expression in the colon through histone
deacetylase inhibition (32, 33). Moreover, butyrate elicits biolog-
ical effects by binding to G protein-coupled receptors, namely
GPR109A and GPR43. Butyrate serves as an endogenous agonist
for GPR109A, expressed in the colonic epithelium, adipose tissue,
and on immune cells, while GRP43 is activated by all three SCFAs
(34). The activation ofGPR109A results in a decrease of intracellu-
lar cAMP-levels accompanied by controlling electrolyte and water
absorption, thereby potentially affecting the incidence of diarrhea
(35). Activation of GPR109A by butyrate was found to impose
anti-inflammatory properties in colonic macrophages and DCs
and enabled them to induce the differentiation of Tregs and IL-10
producing T cells. Furthermore, GPR109A signalingwas shown to
be decisive for butyrate-mediated induction of IL-18 in the colonic
epithelium (36). Comparative analysis in GF mice and their con-
ventionally colonized counterparts revealed markedly reduced
SCFA concentrations in the intestines of GF mice. Application
of SCFAs via drinking water restored colonic Treg homeostasis
and function in GF mice, suggesting that their lack of SCFAs
may account at least partially for their immune defects, especially
their reduced colonic Treg numbers (37). In a murine model of
colitis, dextran sulfate sodium (DSS)-induced inflammation inGF
mice was ameliorated through additional application of acetate.
Conventionally colonized mice lacking Gpr43 showed a markedly
increased inflammatory response following DSS application as
compared to wild-type (wt) mice. Subsequent acetate application
via drinking water resulted in a decrease of colonic inflammation
but only in wt mice. Additional acetate application in Gpr43 / 
mice did not lead to alterations in the severity of inflammation
indicating that the protective effect of acetate seen in wt mice
occurred through binding to GPR43 (38). Most recently, Mackay
and colleagues provided evidence that diet deficient or low in
fiber content exacerbates colitis induced by DSS, whereas a high-
fiber diet was shown to exert a protective effect. Moreover, it
was demonstrated that fiber mediates its protective properties via
activating the NLRP3 inflammasome (39).
Given the aforementioned tremendous metabolic functions of
the intestinal microbiota, the question raises whether inflam-
mation in peripheral tissues is also influenced by intestinal
microbiota-derived metabolites. Recently, Marsland and col-
leagues found evidence that dietary fermentable fiber and SCFAs
are capable of shaping the immunological environment not only in
the murine intestine but also in the lung (40). Oral administration
of a high-fiber diet was accompanied by increased circulating
SCFA levels and concomitant protection against allergic inflam-
mation in the lung following exposure to house mite extract
(HM) through intranasal administration. By contrast, feeding
mice with a low-fiber diet resulted in decreased SCFA levels
and an increase of allergic airway disease in response to HM
application. Accordingly, histological sections revealed enhanced
eosinophilic and lymphocytic infiltrates in the airways of mice
fed a low-fiber diet as well as enhanced concentrations of IL-
4, IL-5, IL-13, and IL-17A in lung tissue homogenates. The
detected differing outcome in response to HM exposure under-
lines the impact of SCFAs on shaping the immunological envi-
ronment in the lung, thereby impinging on the severity of allergic
inflammation.
Intestinal Microbiota in Disease – Changes in the
Gut Microbial Ecosystem
Changes in the microbiota composition display a hallmark of
CD, commonly described as dysbiosis. Individuals with IBD
have been characterized by marked qualitative and quantitative
changes in their microbiota composition (41). Several culture-
dependent and -independent analyses focusing on the microbiota
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profile of CD patients revealed less complex microbiota profiles
and higher numbers of mucosa-associated bacteria compared
to healthy individuals (41–45). Metagenomic-based studies have
reported a reduction in members of the phyla Bacteroidetes and
Firmicutes in patients suffering from CD or UC (41, 46, 47).
Among members of the Firmicutes phyla, significant reductions
in the butyrate-producing bacterium Faecalibacterium prausnitzii
(F. prausnitzii) have been observed repeatedly in CD patients (7,
48). This bacterium displays anti-inflammatory properties, which
have been intensively studied both in vitro and in vivo. Stimulation
of peripheral blood mononuclear cells with F. prausnitzii induced
very low levels of the pro-inflammatory cytokines IFNγ and IL-
12 paralleled by high levels of IL-10 (48). These in vitro effects
were confirmed in vivo by using a 2,4,6-trinitrobenzenesulphonic
acid (TNBS)-induced model of colitis. Oral administration of F.
prausnitzii markedly reduced the severity of TNBS colitis and
tended to rectify the dysbiosis associatedwith colitis in thismodel.
Follow-up studies after ileal resection provided evidence that
a low proportion of F. prausnitzii on resected ileal mucosa of
CD patients was associated with an increased risk of endoscopic
recurrence after 6months.
The changes in abundance and biodiversity of intestinal
microbiota during inflammation are further characterized by an
increase of members associated with the Proteobacteria and Acti-
nobacteria phyla. CD patients were shown to harbor increased
loads of Enterobacteriaceae, in particular Escherichia coli belong-
ing to the taxonomic lineages B2 and D (49). Adherent-invasive
E. coli (AIEC) pathovar has been commonly identified in the
intestinalmucosa of patients with CD, particularly associated with
ileal mucosal lesions (50, 51). Isolates of these certain strains of
E. coli were shown to not only adhere to epithelial cells but also
to invade and replicate intracellularly. Moreover, AIEC is able
to survive and replicate within macrophages without triggering
host cell death accompanied by the release of large amounts
of tumor necrosis factor (TNF)-α (52). Compared to healthy
controls, mucosal biopsy specimens from CD patients displayed
a 10-fold higher presence of bacteria that penetrate the mucus
layer. These results from fluorescent in situ hybridization anal-
yses indicate that in CD the microbiota might have closer con-
tact with the mucosa, a hypothesis that will be discussed in a
later section. However, this finding could be explained by the
increased numbers of mucolytic bacteria, such as Ruminococcus
gnavus and Ruminococcus torques, observed in macroscopically
and histologically unaffected intestinal epithelium of CD patients
(53). In 2011, the so far largest cohort study provided a detailed
description of the microbiome in CD patients (54). A lower
occurrence of F. prausnitzii, Bifidobacterium adolescentis,Dialister
invisus, and an uncharacterized species belonging to Clostridium
cluster XIVa as well as a higher number of R. gnavus characterized
the dysbiosis signature of CD patients (54). From a metabolic
point of view, this comes along with an increased mucolytic
and reduced butyrate-producing capacity. Moreover, this study
not only confirmed previous findings but also propounded that
these changes were markedly characteristic for the disease as
this profile was not found in unaffected relatives of analyzed
patients.
Intestinal Microbiota in the Pathogenesis
of Crohn’s Disease
Experimental and Clinical Evidence
Over the last decades, a consistent body of evidence has accu-
mulated supporting the role of the intestinal microbiota in pre-
cipitating IBD. Studies in IL-2- and IL-10-deficient mice were
one of the first highlighting the role of the intestinal micro-
biota in the induction and perpetuation of chronic inflammation.
Spontaneous colitis observed in IL-2 deficient mice when raised
under specific-pathogen-free (SPF) conditions was unverifiable in
animals with the same genetic background bred under GF condi-
tions. Similarly, IL-10-deficient animals developed an attenuated
inflammation with regard to disease severity and expansion when
kept in a facility with a defined microbial environment (55, 56).
Subsequently, Tbet-deficient mice were shown to develop chronic
colitis with a histopathological similarity to humanUC. The study
revealed also a correlation of the presence of Proteus mirabilis and
Klebsiella pneumoniae and colitis in these animals. Furthermore,
healthy wt mice developed chronic colitis upon co-housing with
T-bet / /Rag2 /  mice (TRUC) or following gavage of feces
from TRUC mice (57, 58). These data indicate that loss of T-bet
influences bacterial populations to become colitogenic and that
colitis is transferable to genetically intact hosts. More recently,
studies in TNFdelta ARE mice provided clear experimental evidence
for the causal role of bacterial dysbiosis in the development
of chronic small intestinal inflammation. Deletion in the TNF
adenosine–uracil (AU)-rich elements (ARE) leads to TNF-driven
spontaneous small intestinal inflammation, characterized by both
transmural manifestation and a predominant ileal involvement,
thereby mimicking key features of human CD pathology (59).
Haller and colleagues assessed the impact of intestinal bacteria in
this model of ileitis by using different hygienic conditions (GF,
SPF, and conventional housing) as well as antibiotics. CD-like
ileitis development was completely absent in GF mice. Antibi-
otic treatment resulted in an amelioration of disease severity
and a recurrence of inflammation was observed following the
relapse ofmicrobiota composition.Moreover, transfer of dysbiotic
cecal microbial communities from SPF–TNFdelta ARE mice into
GF recipients resulted in the development of ileitis, mimicking
inflammation severity of corresponding donors (60). These afore-
mentioned studies just provide examples for the experimental
evidence that has accumulated over the last years.
Event though CD can manifest anywhere along the human ali-
mentary tract, it ismainly observed in areas containing the highest
concentrations of bacteria (i.e., terminal ileum and colon). One of
the first clinical references for the involvement of the intestinal
microbiota in disease pathogenesis came from experiments show-
ing that diversion of the fecal stream from an inflamed segment of
the small intestine improved symptoms of CD patients. Further-
more, restoration of fecal stream and postoperative exposure of
the neoterminal ileum to luminal contents induced inflammation,
indicating that the microbiota acts as a trigger in postoperative
recurrence of CD (61, 62). Numerous arguments in favor of the
involvement of the human microbiota in disease pathogenesis
have emerged over the last years (Table 2).
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TABLE 2 | Clinical evidence – involvement of the human microbiota in
Crohn’s disease pathogenesis.
Arguments on behalf of the
involvement of intestinal microbiota in CD
Reference
Feacal stream diversion improves symptoms of CD (62)
Reinfusion of luminal contents results in recurrent disease (61)
Antibiotic therapy is associated with clinical improvement (63–65)
Mucosal barrier defects and increased translocation (66, 67)
Higher loads of mucus-associated bacteria (42)
Higher concentrations of mucolytic bacteria (53)
Decrease in Faecalibacterium prausnitzii (41, 46, 48)
Decreased concentrations of AMP (68)
CD susceptibility genes: involvement in killing of intracellular
bacteria and secretion of AMP
(69–75)
Siblings of CD patients exhibit mucosal dysbiosis (76)
CD, Crohn’s disease; AMP, antimicrobial peptides.
Although there has accumulated a large body of experimen-
tal and clinical evidence supporting the role of dysbiosis in the
pathogenesis of CD, it is still up for discussion whether these
alterations in the gut microbiota composition represent a cause
or a consequence of chronic intestinal inflammation. Taking into
account that the development of inflammation was shown to be
dependent on the presence of a gutmicrobiota in different murine
models and given the insufficient data to recommend probiotics
for use in CD implies a pathogenetic role (55, 56, 77, 78). Investi-
gations on fecalmicrobiota composition in first-degree relatives of
patients with IBD have coined the term “predysbiosis.” As already
outlined above, several studies indicated a significant impact of
the host genotype on the composition of the intestinal microbiota.
Relatives of CD patients are at much higher risk of developing
CD as compared with the general population. The risk of falling
ill is highest in first-degree relatives, especially siblings, and also
extends to more distant relatives (54, 79). The relative risk of
developing CD was shown to be over 30-fold higher in siblings of
patients with CD compared to that of the general population (76).
Moreover, an over 50-fold increase in the incidence of IBD was
reported withinmultiply affected families (80, 81). Unaffected rel-
atives of CDpatients were found to have a different composition of
their intestinal microbiota compared to healthy controls without
familial predisposition (54). This subclinical dysbiosis observed in
asymptomatic relatives was different from the dysbiosis detected
in CD patients and was characterized by lower numbers of both
Collinsella aerofaciens and an unspecified member of the E. coli –
Shigella group as well as higher numbers of the mucolytic bac-
terium R. torques compared with healthy subjects. R. torques, a
non-butyrate-producing member of the Clostridium cluster XIVa
is capable of degrading gastrointestinal mucin. In contrast to the
dysbiosis detected in CD patients, the subclinical dysbiosis in
their relatives was not characterized by a diminished butyrate-
producing capacity but enhanced mucin degradation might be
assumed in these individuals. Given the differences between the
observed dysbiosis in CD patients and the subclinical dysbiosis
in unaffected relatives, the results from this cohort study suggest
that a “predysbiosis” may precede the clinical manifestation of
CD. Moreover, the increased numbers in mucolytic bacteria let
one suppose that an enhanced mucin degradation capacity of the
intestinalmicrobiota represents an interim step, leading fromnor-
mobiosis to the investigated dysbiosis among the patient cohort
(54). In a recently published study, Hedin and colleagues focused
on the mucosal microbiota in healthy siblings of CD patients and
described amucosal dysbiosis characterized by a reduced diversity
of core microbiota and a lower abundance of F. prausnitzii in
these at risk individuals. The lower abundance of F. prausnitzii
is also one of the convincingly observed species-specific findings
in CD patients’ dysbiosis, therefore also suggesting the causative
role rather than being a consequence of chronic inflammation
(76). Further arguments in favor for an etiological contribution of
dysbiosis in CD are provided by the transmissibility of inflamma-
tion to genetically susceptible hosts as demonstrated in numerous
in vivo models. However, similar patterns of microbial changes
in diverse hosts as well as the fact that inflammation per se is
capable of inducing dysbiosis pleads for the theory of dysbiosis as
a consequence of the inflammatory milieu. The fact remains that
the alteredmicrobial composition entails metabolic consequences
and subsequent changes in the intestinal milieu deriving from the
variety of essential functions provided by the intestinalmicrobiota
and the crosstalk between the microbiota and the host immune
system.
Host–Microbiota Crosstalk – Innate
Mechanisms for Maintaining Intestinal
Homeostasis
The innate immune system consists of the intestinal epithelium
and cells of the innate immune system, such as neutrophils,
DCs, monocytes/macrophages, and innate lymphoid cells (ILCs).
The luminal surface of the gastrointestinal tract with approxi-
mately 300–400m2 represents the largest interface between the
host and the environment. The diverse and abundant indigenous
microflora exists in close proximity to the immune system of
the intestinal mucosa and immune cells in the underlying tissue.
Moreover, the gastrointestinal mucosa is continuously exposed to
antigens derived from the food and has to deal with pathogenic
microorganisms that can cause tissue damage. The intestinal
immune system therefore possesses multiple layers of protection
to respond against invading bacteria, thereby limiting their expo-
sure to the systemic immune system while maintaining tolerance
toward luminal bacterial antigens and food antigens. Given that a
dysregulated immune response toward components of the intesti-
nal microbiota is thought to be a fundamental pillar of chronic
intestinal inflammation development, the complex interaction of
the host with the plentiful intestinal microbiota has to be precisely
regulated.
Barriers of Protection
The Intestinal Mucus Layer – A Protective Blanket
The intestinal epithelium lies at the interface between the intesti-
nal lumen and the gastrointestinal-associated lymphoid tissue,
thereby building the first barrier against excessive microbial
translocation to the lamina propria (82). The intestinal epithelium
itself is covered with a mucus layer constituting the first physical
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barrier to luminal antigens. Mucus is secreted by goblet cells
and typically contains several major components, which in the
intestine comprise of MUC2 and MUC5AC. These densely gly-
cosylated proteins are resistant to digestive enzymes and give the
mucus its gel-like properties (7). The type of mucus organization
in the small and large intestine are clearly different. The small
intestinal mucus fills the luminal space between the villi and is not
attached to the epithelial surface. Antimicrobial products such as
AMPs derived from epithelial cells and Paneth cells as well as IgA
interfuse with the mucus secreted from the crypts, thereby gener-
ating an antibacterial gradient that acts to keep luminal bacteria
away from epithelial surfaces. Of note, the small intestinal mucus
layer is penetrable to bacteria but still provides a diffusion barrier
(83). Themammalian large intestinalmucus is organized in a two-
layer system. The loose outer layer of the mucus is composed
of mucin, diluted antimicrobials, and is the normal habitat for
commensal bacteria, whereas the inner layer is firmly attached
to the epithelial cells, rich in antimicrobials, and displays a low
bacterial density (84). The physiological relevance and protective
function of the mucus layer has best been highlighted in studies
using MUC2 /  mice. Muc2-deficiency was shown to lead to
colonic inflammation accompanied by the presence of bacteria
in direct contact with the intestinal epithelium (85). Moreover,
these animals displayed a much higher susceptibility to infection
by pathogens (86). From studies in GF mice, it emerged that
intestinal microbiota have a role in shaping the colonic mucus
barrier (87). Mice housed under GF conditions have been char-
acterized by an extremely thin adherent colonic mucus layer.
Exposure to bacterial products, such as lipopolysaccharide or pep-
tidoglycan, leads to the re-storage of the mucus thickness to levels
observed in conventionally housed mice. A recently published
work reinforced the assumption that intestinal bacteria affect
the host mucus barrier properties. In this study, two colonies of
C57BL/6 mice were housed and bred in different rooms but both
under SPF conditions. Analysis of the microbiota composition
by 16S rRNA gene sequencing revealed significant differences
at multiple taxonomic levels between the two separately housed
colonies. Interestingly, the two colonies not only differed in their
microbiota composition but also have a different mucus phe-
notype that was shown to be specific for each colony. Whereas
the thickness of the mucus layer was similar in both groups, a
major difference regarding permeability was detected. One colony
displayed amucus layer impenetrable to bacteria, the other colony
had an inner mucus layer that was penetrable to both bacteria and
beads. The causal role of the intestinal microbiota in the detected
mucus phenotypes was underpinned by subsequent experiments
showing that the different mucus properties were transmissible by
transfer of cecal microbiota to GF mice (88). Although genetic
risk loci inMUC1 andMUC19 have been identified in IBD, there
is only limited and widely varying data regarding changes of the
mucus layer during CD (3). One study investigated the thickness
and continuity of the mucus barrier in rectal biopsies from CD
patients but only provided a small number of cases (89). In this
study, no significant differences between CD patient specimens
and controls were found. Another study reported a depletion
of the mucus layer at inflamed sites of the gut of CD patients
compared to healthy controls aswell as compared to non-inflamed
areas in the same patient (90). Of note, there were no significant
differences regarding the thickness of the mucus layer between
non-inflamed areas of CD patients and healthy controls. These
results are in direct contrast to previously published data mea-
suring the thickness of the colonic mucus in surgically resected
specimens from CD patients. Pullan and colleagues reported
increased values compared to healthy controls (91). As briefly
outlined above, the colonic mucus is organized in two layers.
Given the contrary results, one has to consider that in the study
showing a thicker mucus layer in CD patients a PAS/AB staining
technique was used. During PAS/AB staining variable amounts
of the loose outer mucus layer might remain thus contributing
to the larger thickness observed in CD specimens. The different
results might also reflect different stages of disease and moreover,
inflammation in CD is characterized by a discontinuous appear-
ance therefore a general mucus barrier dysfunction is unlikely to
occur.
Antimicrobial Peptides and Antibodies
A substantial mechanism for controlling the contact between
intestinal epithelial cells and luminal antigens is the secretion
of AMPs. One of the intensive studied proteins among AMPs
is the antibacterial lectin RegIIIγ produced by multiple epithe-
lial lineages, including enterocytes and Paneth cells and capa-
ble of mediating direct killing of Gram-positive bacteria (92).
Mouse RegIIIγ and its human counterpart HIP/PAP are primarily
expressed in the small intestine. Inflammatory conditions were
shown to increase the expression of RegIIIγ in the mouse intes-
tine, likewise HIP/PAP expression is increased in the mucosa of
IBD patients (93). Reconstitution of GF mice with an intestinal
microbiota from conventionally raised mice resulted in a sharp
increase in the abundance of RegIIIγ transcripts in Paneth cells
(92). This study also explored the mRNA expression of RegIIIγ
duringweaning reflecting an early stage of intestinal development.
RegIIIγ mRNA levels showed a sharp upward movement that was
missing in GF controls. To further unravel the host–microbial
interactions underlying the regulation of RegIIIγ, Cash and col-
leagues investigated the dynamic of this antibactericidal pro-
tein in mice lacking IgA. Bacteroides thetaiotaomicron and Liste-
ria innocua – under state conditions compartmentalized in the
intestinal lumen – showed an increased mucosal adherence in
the absence of IgA and were found to substantially trigger a vast
RegIIIγ mRNA increase in GF mice lacking IgA. These results
indicate that an increased contact between microbiota and the
intestinal epitheliumdrivesRegIIIγ expression. The role ofRegIIIγ
as a key element of the intestinal mucosal defense has further
been validated in murine RegIIIγ-deficiency studies that revealed
an increased bacterial colonization of the intestinal epithelial
surface (94).
Another major group of AMPs is represented by α-defensins,
largely produced by small intestinal Paneth cells and β-defensins
produced by most epithelial cells (95). Human defensin (HD)-5
and HD-6, both belonging to the group of α-defensins as well as
the human β-defensin (HBD)-1, are expressed constitutively (16).
HBD-2 and HBD-3 belong to the group of inducible defensins
and are expressed in the large intestine. The induction was shown
to be mediated by pro-inflammatory cytokines, such as IL-1β,
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involving NF-κB pathways (96, 97). Induction was also observed
following the recognition of intestinal bacteria by pattern recog-
nition receptors (PRRs) (98). Decreased defensin levels can result
in a weakening of the intestinal epithelial barrier and might be
involved in the pathophysiology of chronic inflammation. Ileal
CD is associated with reduced expression of Paneth cell-derived
α-defensins and colonic CD was reported to be associated with
reduced expression of β-defensins by enterocytes (68). Next to
their antimicrobial property, α-defensins possess an additional
homeostatic role in regulating and shaping the composition of the
small intestinal microbiota. Transgenic expression of DEFA5 (α-
defensin) comes along with a significant decrease of members of
the phylum Firmicutes, paralleled by an increase in the percent-
age of Bacteroidetes. Moreover, transgenic expression of DEFA5
also causes a loss of SFB and concomitantly Th17 in the lamina
propria (99).
A third immune mechanism serving to control the microbiota
and reduce the contact between intestinal bacteria and epithelial
cells is the secretion of IgA by lamina propria plasma cells (100).
DCswithin the Peyer’s patches and subepithelial dome region con-
tinuously sample luminal bacteria. Bacteria- and antigen-loaded
DCs interact with and prime T- and B-cells in the Peyer’s patches
or find their way to the gut-draining mesenteric lymph nodes via
the afferent lymphatics. The interaction of antigen-bearing DCs
with naïve B cells induces the activation and differentiation of
naïve B cells to IgA producing plasma cells. These plasma cells
leave the Peyer’s patches or mesenteric lymph nodes, respectively,
enter the systemic circulation via the efferent lymphatics and
return to the intestinal lamina propria where they secrete IgA into
the intestinal interstitium. The secreted IgA is specific for com-
mensal microbiota, subsequently taken up by epithelial cells and
delivered to their apical surface. When released into the intestinal
lumen, IgA binds to commensal microbiota, thereby limiting their
capability to penetrate the epithelial barrier (7, 101). Remarkably,
live bacteria transported by DCs do not gain access to the sys-
temic circulation at any time thus are not able to induce systemic
immune responses. Recent studies provide evidence that goblet
cells, supposedly purely secretory cells, also act as luminal sensors
for the innate immune system.McDole and colleagueswere able to
show that in the absence of inflammation, small intestinal goblet
cells act as passages delivering low molecular weight soluble anti-
gens from luminal to CD103+ DCs in the underlying lamina pro-
pria (102). The interconnection between goblet cells andDCswith
tolerogenic potential illustrate that goblet cells contribute to the
communication between luminal antigens and the innate immune
system.
Taken together, these aforementioned innate barriers of pro-
tection are crucial for intestinal homeostasis. Moreover, a finely
balanced interplay between the intestinal microbiota and cells
of the host immune system is indispensable for ensuring the
functionality of these barrier mechanisms.
Epithelial Barrier and the Crosstalk Underneath
In contact with the inner mucus layer, there is the intestinal
epithelium consisting of fourmain types of epithelial cells, namely
enterocytes, enteroendocrine cells, goblet cells, and Paneth cells.
The intestinal epithelium contributes to absorption, digestion as
well as secretion, and functions as amucosal barrier (84).Mucosal
barrier integrity is maintained by tight junctions, desmosomes,
and adherence junctions. Impairment of the epithelial barrier is
accompanied by increased intestinal permeability and bacterial
translocation leading to persistent immune activation, a condition
that has been observed in both CD and UC patients (103). In
health, only small amounts of luminal antigens are allowed to
pass across the epithelium.Murinemodels displaying an impaired
barrier function were shown to develop intestinal inflammation.
Junctional adhesion molecule-A (JAM-A) is a key structure of
tight junctions and mandatory for controlling cell migration
into the underlying tissues. Studying of CD tissue specimens for
JAM-A expression revealed a loss of epithelial JAM-A expres-
sion (104). In line with these findings are the decreased levels
of further tight junction proteins, such as claudins, observed in
CD (66).
Lying between the luminal microbiota on the one side and
immune cells in the lamina propria on the other, the intesti-
nal epithelium functions to communicate with both. Sensing
of microbial antigens by epithelial cells as well as by innate
immune cells, such as macrophages and DCs, is crucial for main-
taining intestinal homeostasis and is mediated by PRRs (95).
These receptors include the family of toll-like receptors (TLRs) as
well as intracytoplasmatic receptors, such as NOD-like receptors
(NLRs). Polymorphisms in TLRs and NLRs have been impli-
cated in increased susceptibility to IBD (3, 69). Whereas TLRs
are capable of detecting a variety of bacterial components, such
as lipopolysaccharide, lipoproteins, and CpG DNA, NLRs rec-
ognize peptidoglycan molecules on the bacterial cell wall (105).
Activation of PRRs results in down-stream signaling cascades
that are widely mediated by Myd88. MyD88 represents a cytoso-
lic adaptor protein, equipped with a toll/IL-1 receptor (TIR)
domain, thereby able to directly bind TLRs (106). Once engaging
TLRs, MyD88 mediates MAP kinase activation, recruitment of
a variety of signaling molecules and drives nuclear transloca-
tion of NF-κB and subsequent production of pro-inflammatory
cytokines. Given the abundance of commensal antigens in the
intestinal lumen, it is crucial that activation of PRRs not exclu-
sively drives inflammatory responses. Excessive stimulation can
lead to detrimental inflammation. Otherwise, repetitive stimula-
tion of TLRs due to commensal bacterial exposure was shown
to result in a down-regulation of the NF-κB pathway and stim-
ulation of AMP production (1). Moreover, triggering of PRRs
also promotes antigen presenting cell maturation and is involved
in proliferation of Tregs (107). Already about one decade ago,
Rakoff-Nahoum and colleagues provided experimental evidence
that the recognition of the commensal microbiota by TLRs is
crucial for maintenance of intestinal epithelial homeostasis and
required for regeneration after mucosal injury (108). TLR expres-
sion and activation has to be tightly regulated and this regu-
lation is exerted by a number of mechanisms, such as adjust-
ment of their expression, their localization, and their positioning
within the tissue. Most surface TLRs are principally found on
the basolateral side of IEC and are only up-regulated during
inflammation (109).
Punctilious sampling and processing of luminal antigens is
essential for avoiding the development of intestinal inflammation
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and establishing and sustaining a healthy relationship between the
commensal microbiota and the host. DCs are an indispensable
element in this crosstalk as they are continuously exposed to
antigens derived from commensal microbiota, dietary products,
and intestinal pathogens. The ductility of DCs is warranted by
their ability to adapt to influences of the microenvironment. In
this context, different DC populations with different functionality
have been described. Gut-resident DCs display tolerogenic func-
tions as they encounter and sense commensal bacteria and act,
for example, by inducing a highly tolerogenic response through
differentiation and expansion of Tregs (110, 111). The triangular
crosstalk between epithelial cells, DCs, and the intestinal micro-
biota is orchestrated by PPR signaling. Using an in vitro model,
intestinal epithelial cells were shown to release cytoprotective
factors, such as thymic stromal lymphopoietin and transforming-
growth factor-β upon activation of TLR-signaling, leading to the
presence of a predominantly tolerogenic DC phenotype. These
tolerogenic DCs were found to secrete IL-10, leading to an
immune response dominated by Tregs (112).
Even though the intestinal epithelium with its numerous lines
of protection provides a barrier separating luminal antigen from
the underlying tissue, it is inevitable that antigens gain access
to the lamina propria. As mentioned above, this might not
only occur through injury or infection but also happens when
commensals undergo epithelial cell transcytosis or transloca-
tion via M cells or DCs (113). In response to transforming-
growth factor-β and IL-8, chemokines abundant in the extra-
cellular matrix of the lamina propria, circulating blood mono-
cytes gather to the non-inflamed lamina propria where they
become resident intestinal macrophages. Located strategically
in the subepithelial lamina propria, intestinal macrophages are
part of the armament of innate defense mechanisms. The inter-
action between macrophages and microorganisms is mediated
by PRRs, including TLRs and NLRs. In contrast to periph-
eral macrophages, intestinal macrophages were shown to per-
form their defense activities without releasing inflammatory
cytokines while retaining their phagocytic and bacteriocidal activ-
ity. Consequently, intestinal macrophages do not provoke a
pro-inflammatory cytokine milieu in the non-inflamed mucosa
despite the close proximity to and interaction with immunostim-
ulatory microorganisms. This so-called “inflammatory-anergy”
was shown to be at least in part attributable to matrix-
bound transforming-growth factor-β and Tregs causing a down-
regulation of PRRs and related adapter proteins, resulting in
NF-κB inactivation (113, 114). In the case of inflammation or
intestinal infection, blood monocytes accumulate in the lamina
propria and actively combat invading microorganisms through
uptake and degradation, including the release of inflammatory
mediators.
Over the last decade, an emerging family of innate immune
cells, termed ILCs has been characterized. Since ILCs reside pri-
marily at mucosal sites and are enriched at mammalian barrier
surfaces, including the intestine, these cells are in close prox-
imity to environmental antigens and commensal microbiota in
particular. Commensal microbiota were found to provide signals
for the development, differentiation, and function of ILCs and
this crosstalk, the interplay between the microbiota and ILCs is
indeed an area of intense research. ILCs have been shown to
contribute to tissue repair and remodeling at barrier surfaces
and were found to influence inflammatory conditions, thereby
orchestrating host–commensal relationships (115). Being derived
from an Id2-dependent lymphoid progenitor cell population, ILCs
are of lymphoid origin but do not require antigen receptors gen-
erated by somatic recombination (116). Based on transcription
factors required for their development, their cytokine produc-
tion patterns and surface markers, the family of ILCs is cate-
gorized in three main branches. In brief, group 1 ILCs (ILC1)
are Tbet- dependent and are composed of ILC1s and NK cells.
ILC1s respond to IL-12 and IL-18 and produce IFN-γ. Group 2
or GATA3+ ILCs secrete IL-5, IL-9, IL-13, and amphiregulin in
response to IL-33 and IL-25. Finally, group 3 ILCs (ILC3) express
RORγt and include lymphoid tissue-inducer (LTi) cells and nat-
ural cytotoxicity receptor (NCR) expressing ILCs. Group 3 ILCs
respond to IL-1β and IL-23 and are the main producers of IL-17
and IL-22 (117). Given the spatial proximity of ILCs and commen-
sal microbiota in the intestine, multiple groups have investigated
the possible role for commensal microbiota in the development of
ILCs. Studies using GFmice indicated that NK cells and GATA3+
ILCs develop properly without receiving signals from commensal
microbiota (118, 119). Regarding RORγt+ ILCs, there have been
controversial reports on the requirement of commensal micro-
biota for their development. It seems that the development of at
least subsets of RORγt+ ILCs occurs regardless of the presence of
a commensal flora as evident by the presence of LTi cells as well
as the generation of secondary lymphoid structures in the sterile
environment before birth (115, 120, 121). However, the ripening
of intestinal cryptopatches into isolated lymphoid follicles was
found to be compromised in GF mice, suggesting at least a func-
tional impairment in some populations of LTi-like RORγt+ ILCs
(122). Several groups reported normal development of RORγt+
ILC subsets in both GF and antibiotic treated mice (115, 123,
124). By contrast, other studies proposed that commensal bacteria
are capable of enhancing the development of NCR+ RORγt+
ILCs and IL-22 production. IL-22 produced by this population
in turn contributed to epithelial homeostasis by regulating genes
involved in tissue repair and antimicrobial defense mechanisms,
such as RegIIIβ and RegIIIγ (125–127). Factors accounting for
these differing results may relate to host genetics, a differential
presence of other cell types and cytokines andnot least to a varying
exposure to non-live bacterial- or diet-derived signals. Although
it seems that the development of most ILCs is not reliant on bac-
terial interaction, signals derived from the commensal microbiota
directly affect the function of ILCs. The regulation of ILC function
by commensal bacteria can happen indirectly or directly through
engagement of PRRs on ILCs themselves. For instance, human
NK cells were shown to express functional TLR2 and TLR9 (128,
129). Moreover, stimulation of human RORγt+ ILCs with TLR2
agonists resulted in IL-2 productionwhich in turn enhanced IL-22
expression (130). In addition, there is accumulating evidence that
NCRs ofNK cells andNCR+ RORγt+ ILCs act as direct sensors of
components of the commensal bacteria (131–133). Next to direct
signaling through TLRs and NCRs, different groups provided
evidence that the aryl hydrocarbon receptor (AhR), expressed by
RORγt+ ILC3s and well known for its critical function in ILC
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development and IL-22 production has also a role in the com-
mensals regulatory function. More specifically, the AhR can be
stimulated by ligands derived from the tryptophan metabolism of
commensal microbiota, thereby having an intermediate position
between direct and indirect regulation (134). In addition to direct
regulation, commensal bacteria also take advantage of an indirect
route of influencing the function of ILCs via triggering cytokine
signals from epithelial cells or other innate immune cells. As
one example, commensal bacteria captured by DCs lead to the
induction of IL-12 that acts on ILC1s by stimulating their IFN-
γ production that in turn accelerates macrophage phagocytosis
(116). Next to the effects of the commensal microbiota on ILCs,
there is evidence that ILCs are capable of influence the microbial
community. This reciprocal interaction is, for example, simply
attributed to signals derived from ILCs that act on the intestinal
permeability and thus affect bacterial translocation.
Due to displaying a major source of IL-17 and IL-22, ILC3s are
supposed to be critical for the promotion of inflammation and
tissue repair in the intestine aswell as for dealingwith extracellular
bacteria (135). Murine models provided evidence that NCR+
ILC3s rapidly response to infection with the enteric pathogen Cit-
robacter rodentium by producing IL-22, which is essential for host
protection. This ILC3 response is promoted by the occurrence of
a positive feedback loop stimulating DCs to the production of
both lymphotoxin-β and IL-23 (124, 136). IL-17 and IL-22 derived
from ILC3s promotes neutrophil recruitment to the intestine and
stimulates inter alia the production of RegIIIγ, RegIIIβ, as well as
mucus production, thereby also pointing out the important role
of ILC3s in tissue repair (135, 137). Moreover, ILC3s were shown
to have the potential to regulate not only innate but also adaptive
immune responses, a capacity thatmight be crucial especially with
regard to chronic inflammatory disorders like IBD. Mortha and
colleagues recently reported that ILC3s are the primary source of
granulocyte-macrophage colony-stimulating factor (GM-CSF) in
the intestine. GM-CSF production was depend on and regulated
by the ability of macrophages to sense commensal microbiota
and produce IL-1β. ILC3-derived GM-CSF influenced myeloid
cell homeostasis and was essential for the generation of sub-
sequent Treg responses toward food antigens and maintenance
of oral tolerance (138). Furthermore, mouse and human ILC3s
were also found to express MHCII, and directly interact with
CD4+ T cells. Most interestingly, murine studies revealed that
depletion of ILC3-intrinsic MHCII leads to the development of
spontaneous CD4+ T cell-driven microbiota-dependent inflam-
mation (139, 140).
Of note, this only provides a brief insight into the complex
world of ILCs but states incontrovertibly that the emerging family
of ILCs is essential in the context of the crosstalk between the
microbiota and the innate immune system, thereby displaying a
key determinant in regulating the host–commensal relationship.
Conclusion
The innate immune system provides multiple layers of protec-
tion to regulate and control interactions between the intestinal
microbiota and the host. However, the functionality of these
protective mechanisms depends on and is positively affected by
finely balanced signals derived from the commensal microbiota,
thereby ensuring their reliability and performance. In CD, these
mechanisms of defense and tolerance are impaired at multi-
ple levels. Intestinal dysbiosis and concomitant changes of the
intestinal luminal milieu and environment weaken the intestinal
epithelial barrier and entail an increased epithelial permeabil-
ity. Epithelial barrier dysfunction is followed by an increase of
translocation to the lamina propria, where defective handling of
antigens might elicit a strong inflammatory response, maintained
and enhanced by ineffective phagocytosis, and bacterial clearance
as well as impairment of adaptive immune responses. Although
it remains unclear, if dysbiosis precedes disease or results from
active inflammation, the changes observed during active CD have
a lasting and debilitating effect on the numerous hostmechanisms
that function to maintain homeostasis. Two recent randomized
controlled trials provide additional insight by indicating that re-
establishing of the intestinal microbiota composition by fecal
microbiota transplantation (FMT) ameliorates active UC in a
patient subgroup. The first trial conducted by Moayyedi et al.
randomly assigned patients with active UC to receive either FMT
via enema from healthy anonymous donors or placebo (water via
enema) once weekly for a period of 6weeks (141). The second
study also investigated the therapeutic impact of FMT in patients
with UC (142). Remarkably, in this study by Rossen et al., autol-
ogous fecal microbiota served as control and the administration
route of FMT was via nasoduodenal tube. In brief summary and
without discussing all study characteristics and statistical out-
comes in detail, the decisive insight obtained from these studies
is that responsiveness to FMT was accompanied with changes
in the microbiota composition and especially with a significant
increase of the patients microbial diversity. Moreover, patients
with a recent diagnosis of UC seem to be more likely to respond
to FMT. Given that seven of the nine responding patients in the
study conducted by Moayyedi et al. received fecal material from
the same single donor, this leads to the suggestion of a donor-
dependent effect and underlines the relevance of the microbiota
composition in intestinal homeostasis. Furthermore, it points out
that intestinal dysbiosis – irrespective of being cause or conse-
quence – comes along with changes in the intraluminal milieu
and together with a genetic predisposition might be capable of
triggering a vicious cycle resulting in an abnormal inflammatory
response.
This increasing evidence on the interplay of the intesti-
nal microbiome, barrier, and intraepithelial as well as mucosal
immune cells displays a complex network that is tightly regulated.
Nevertheless, the data discussed indicate several target structures
that require in-depth exploration, such as targeting the luminal
site via a defined change in the microbiota composition or via
selected nutritional restriction that strengthen barrier function
and exert anti-inflammatory effects on immune cells. FMT will
have to be replaced by a defined administration of a bacterial
mix. The definition of this “mix” or additional food compounds
that influence the mucosal balance will be the center of research
and might ultimately provide novel therapeutic targets not only
for IBD.
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